Does Anthem (Elevance Health) Cover Zepbound?

Anthem's Current Zepbound Coverage Policy

Anthem (Elevance Health), the second-largest commercial health insurer in the United States with over 45 million medical members, covers Zepbound on most of its commercial PPO and HMO formularies. Coverage is not automatic. You need prior authorization, and most plan designs also require step therapy documentation before Anthem will approve tirzepatide specifically.

The policy applies to the FDA-approved indication for chronic weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. Anthem's clinical pharmacy team reviews each request against internal medical policy criteria that closely mirror the FDA-approved prescribing information and the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity. Plans administered through Anthem's subsidiary, IngenioRx (now Elevance Health Pharmacy), use the same medical policy framework, though specific tier placement can vary by employer group contract. Self-funded employer plans using Anthem as a third-party administrator may apply different criteria entirely, so always verify your specific plan's drug formulary through the Anthem member portal or by calling the number on your insurance card.

What Formulary Tier Is Zepbound on Anthem?

Zepbound sits on a non-preferred specialty tier (Tier 4 or Tier 5) across most Anthem commercial formularies, which means higher cost-sharing than preferred brand drugs. Your copay or coinsurance depends on your specific benefit design.

A Tier 4 placement typically carries 25% to 40% coinsurance after deductible on Anthem PPO plans. Tier 5 specialty designations may push coinsurance to 30% to 50%. On a $1,059 monthly list price, that translates to $265 to $530 per fill before any savings card offset. Some Anthem plans apply accumulator adjustment programs that prevent manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. Ask your benefits department whether your plan uses an accumulator or maximizer program, because this directly affects your annual costs. Anthem's formulary placement reflects the competitive dynamics in the GLP-1/GIP receptor agonist class. Semaglutide (Wegovy) often occupies a preferred position on Anthem formularies, which is why Anthem requires step therapy through semaglutide before approving tirzepatide in many plan designs. The American Association of Clinical Endocrinology's 2023 obesity treatment algorithm does not rank one agent over the other, but payer formulary committees weigh net cost alongside efficacy data.

Prior Authorization Requirements

Anthem's prior authorization for Zepbound requires your prescriber to document specific clinical criteria. The process is moderate in difficulty. Most approvals or denials come back within 5 to 14 business days for standard requests, or 24 to 72 hours for urgent requests.

Your prescribing clinician must submit the following to Anthem's utilization management team: a confirmed BMI of 30 or greater (or 27 or greater with a qualifying comorbidity), documentation that the patient has attempted lifestyle modifications (diet and exercise) for at least 6 months, evidence that the patient has tried and failed (or has a contraindication to) at least one formulary-preferred anti-obesity medication, and confirmation that the prescriber will reassess weight loss response at 12 to 16 weeks. Anthem typically expects at least 5% body weight reduction by week 16 for continued authorization. The SURMOUNT-1 trial (N=2,539), published in the New England Journal of Medicine in 2022, demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared with 2.4% for placebo. That data point matters for your PA submission because it establishes the clinical rationale Anthem reviewers use to evaluate expected treatment response. Dr. Ania Jastreboff, the SURMOUNT-1 principal investigator at Yale, stated: "The magnitude of weight reduction with tirzepatide is unprecedented for a non-surgical intervention and redefines the therapeutic ceiling for pharmacological obesity treatment." If your prescriber submits a PA electronically through Anthem's CoverMyMeds portal, turnaround tends to be faster than fax-based submissions. Ask your prescriber's office which method they plan to use.

Step Therapy: What Anthem Requires Before Zepbound

Most Anthem commercial formularies require you to try at least one preferred anti-obesity medication before they approve Zepbound. This is called step therapy, and it is the most common reason for initial Zepbound denials on Anthem plans.

The preferred first-step agent on most Anthem formularies is semaglutide 2.4 mg (Wegovy). Some plans also accept a trial of liraglutide 3.0 mg (Saxenda) or oral semaglutide. Anthem generally defines an adequate trial as 12 weeks at the target or maximum tolerated dose. If you experienced intolerable side effects (persistent nausea, vomiting, or pancreatitis risk) or failed to achieve at least 5% weight loss after 12 weeks on the step-therapy agent, your prescriber can document that failure to satisfy the step-therapy requirement. Contraindications also count. A documented history of medullary thyroid carcinoma, MEN2 syndrome, or a severe hypersensitivity reaction to semaglutide bypasses the step-therapy requirement entirely because the FDA label for Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies. The Endocrine Society guideline recommends that clinicians select anti-obesity medications based on individual patient factors including comorbidity profile, side-effect tolerance, and prior treatment history, which provides clinical support for overriding rigid step-therapy protocols when individualized care demands it.

How to Appeal an Anthem Zepbound Denial

Anthem denials for Zepbound are not final. You have two levels of appeal within Anthem, plus an external review through your state's independent review organization (IRO). The full process can take 30 to 60 days but has a meaningful success rate when clinical documentation is thorough.

Level 1: Internal Appeal. You or your prescriber must file a written appeal within 180 days of the denial. Include the denial letter reference number, updated clinical notes, BMI measurements, prior medication history with specific dates and doses, lab work (HbA1c, lipid panel, fasting glucose if applicable), and a letter of medical necessity from your prescriber. Cite the SURMOUNT trial data and any relevant guideline recommendations. Anthem must respond within 30 calendar days for standard appeals or 72 hours for expedited appeals involving urgent clinical situations.

Level 2: Second Internal Appeal. If Level 1 is denied, you can request a second review. This goes to a different Anthem physician reviewer who was not involved in the original decision. Same documentation standards apply, but this is where peer-to-peer review becomes available. Your prescriber can request a phone call with the Anthem medical director to discuss the clinical rationale directly.

External Review (IRO). If both internal appeals fail, you have the right under the Affordable Care Act's external review provisions to request an independent review. The IRO is a third-party organization certified by your state's department of insurance. IRO reviewers are board-certified physicians in a relevant specialty. They evaluate whether Anthem's denial was clinically appropriate. IRO decisions are binding on Anthem.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "The appeal process for anti-obesity medications is a clinical exercise, not an administrative one. The strongest appeals pair individual patient data with the key trial evidence showing that the requested medication offers a distinct clinical advantage the step-therapy agent did not deliver."

Tips that improve appeal outcomes: include a side-by-side comparison of your weight trajectory on the step-therapy agent versus your treatment goals, attach the SURMOUNT-1 publication as a supporting exhibit, and document any comorbidity improvements (blood pressure reduction, HbA1c change, CPAP pressure reduction) expected from greater weight loss.

Using the Lilly Savings Card with Anthem

Eli Lilly offers a manufacturer savings card for Zepbound that can reduce commercially insured patients' out-of-pocket costs to as low as $25 per month. The card is available to patients with commercial insurance, including Anthem plans. It does not apply to government-funded insurance (Medicare, Medicaid, Tricare, VA).

The savings card covers the difference between your plan's cost-sharing amount and $25, up to a maximum annual benefit. You can enroll at Lilly's Zepbound savings program website. The card works at the pharmacy point of sale and stacks with your Anthem benefits. There is one critical caveat. Anthem plans that use accumulator adjustment programs will not count the savings card value toward your deductible or annual out-of-pocket maximum. This means you could use the savings card all year and still face full cost-sharing once the card's annual cap is reached because your deductible never progressed. According to a 2023 analysis published in JAMA Network Open, accumulator programs affected approximately 20% of commercially insured patients using specialty medications, resulting in higher annual spending compared with patients on standard copay designs. Ask your Anthem plan administrator directly whether your plan uses a copay accumulator before relying solely on the savings card for long-term cost planning.

Zepbound Clinical Efficacy: What the Evidence Shows

Anthem's coverage criteria reference the same clinical trial data your prescriber uses to justify medical necessity. Understanding the numbers strengthens both your PA submission and any appeal.

The SURMOUNT-1 trial randomized 2,539 adults with obesity (BMI of 30 or greater, or 27 or greater with comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo. At 72 weeks, mean weight reductions were 16.0%, 21.4%, and 22.5% for the three doses, respectively, versus 2.4% for placebo (P<0.001 for all comparisons). Over 85% of patients on the 10 mg and 15 mg doses achieved at least 5% weight loss, and more than one-third on the highest dose achieved 25% or greater weight reduction. The SURMOUNT-2 trial, which enrolled 938 adults with both type 2 diabetes and obesity, showed 12.8% and 14.7% mean weight loss with tirzepatide 10 mg and 15 mg at 72 weeks, alongside a 2.1 percentage-point reduction in HbA1c. These dual metabolic benefits are clinically relevant for Anthem PA submissions when a patient has both obesity and type 2 diabetes, because the data demonstrate that tirzepatide addresses two conditions simultaneously.

Tirzepatide's dual GIP and GLP-1 receptor agonist mechanism differentiates it from semaglutide, a GLP-1 receptor agonist only. The SURMOUNT-1 trial was not a head-to-head comparison with semaglutide, but cross-trial comparisons suggest tirzepatide produces approximately 5 to 7 percentage points greater weight loss than semaglutide 2.4 mg. The SURMOUNT-5 head-to-head trial directly comparing tirzepatide 15 mg to semaglutide 2.4 mg showed 20.2% mean weight loss with tirzepatide versus 13.7% with semaglutide at 72 weeks, a statistically significant difference published in Nature Medicine (2024). This data point is particularly useful in appeals after semaglutide step-therapy failure, because it demonstrates tirzepatide's superior efficacy in a direct comparison.

Anthem Medicare Advantage and Medicaid Plans

Anthem's Medicare Advantage and Medicaid managed-care plans generally do not cover Zepbound for weight loss. Medicare Part D excludes anti-obesity medications by statute under the Social Security Act, and most state Medicaid programs follow similar exclusions.

There is one exception pathway. If your prescriber is treating obesity-related type 2 diabetes and can document the primary indication as glycemic control (using the Mounjaro brand of tirzepatide, which is FDA-approved for type 2 diabetes), some Anthem Medicare Advantage Part D plans cover tirzepatide under the diabetes indication. This is an off-formulary coverage pathway for the Mounjaro formulation, not Zepbound specifically. The distinction matters because the FDA approved Zepbound and Mounjaro as separate NDCs with different approved indications, even though both contain tirzepatide. Legislative efforts to add Medicare Part D coverage for anti-obesity medications, including the Treat and Reduce Obesity Act reintroduced in Congress, remain pending. The Congressional Budget Office has estimated that covering anti-obesity medications under Medicare would cost approximately $35 billion over ten years, but projected savings from reduced cardiovascular events, joint replacements, and diabetes complications could offset a significant portion of that expenditure.

What to Do If Your Anthem Plan Excludes Zepbound Entirely

Some self-funded employer plans administered by Anthem explicitly carve out all anti-obesity medications. If your plan has a blanket exclusion, the PA and appeal process described above does not apply because there is no coverage pathway to appeal toward.

Check your Summary of Benefits and Coverage (SBC) document or call Anthem member services to confirm whether anti-obesity medications are an excluded benefit class. If they are, your options include using the Lilly savings card for a cash-pay discount (the card reduces the $1,059 list price for eligible patients), asking your employer's HR department to add anti-obesity medication coverage during the next plan renewal cycle, or switching to an Anthem plan during open enrollment that includes anti-obesity drug coverage. Compounded tirzepatide from 503B outsourcing facilities was available at lower cost during the FDA drug shortage period, but the FDA removed tirzepatide from the shortage list in late 2024, and 503A compounding pharmacies without patient-specific prescriptions face enforcement action. Do not assume compounded tirzepatide remains a legal or safe alternative without verifying current FDA enforcement status.

Patients on Anthem plans with total anti-obesity medication exclusions may still qualify for clinical trials studying tirzepatide in new populations or at different doses. ClinicalTrials.gov lists active Lilly-sponsored studies with no-cost drug supply for enrolled participants.